secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004063
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave
--------------------------------------------------------------------------------

- SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.
- CEO Satyavrat Shukla agrees to paid administrative leave; CFO Esther Rajavelu appointed interim CEO.
- Director Frank Thomas replaces Dr. Ankit Mahadevia as Chairman of the Board.
- Preliminary cash and equivalents of $52.9M as of Dec 31, 2024; runway into mid-2026.
- Phase 3 PIVOT-PO trial enrollment exceeds 60%; on track for full enrollment in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/0001193125-25-004063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/d820907d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer